Check out this CLVS mention in the latest report from DRP Gazett:
3 Short Squeeze Candidates for Interested Traders | June 2, 2021
"Clovis Oncology Inc (NASDAQ: CLVS) is a biotechnology company. Currently, 42% of the float is short. The short interest could be prime for a squeeze as the company is set to present four abstracts featuring data from clinical studies evaluating Rubraca and/or lucitanib and one abstract on real world data of PARP inhibitor usage, during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting to be held virtually, June 4-8, 2021. Which is why now is a good time to look at this biotech company."